Biotectix, LLC announced today the acquisition of all significant assets owned by Chameleon BioSurfaces Ltd. (Cambridge, United Kingdom). Financial terms were not disclosed.
“the Chameleon technology is highly complementary to the conductive thiophene-based polymer materials we are actively commercializing. Importantly, it further solidifies our leading IP position in this field while giving us additional materials options with our co-development partners in the medical device field.”
Chameleon has been a leading developer of advanced polymer coatings for implantable medical devices. The technology utilizes novel electrically conductive polymer coatings for improved biocompatibility, conformal coverage, electrical performance, and drug release. The assets include several issued and pending U.S. and international patents.
Dr. James Arps, General Manager at Biotectix, commented on the purchase that "the Chameleon technology is highly complementary to the conductive thiophene-based polymer materials we are actively commercializing. Importantly, it further solidifies our leading IP position in this field while giving us additional materials options with our co-development partners in the medical device field."
Geoffrey Beanland, Chairman at Chameleon, further noted "all of us at Chameleon are very proud of the progress we've made in the development and use of electropolymerized coatings for drug eluting stents and other life sustaining devices. We are confident that the resources Biotectix can bring to bear will greatly aid in the advancement of this technology."
All Chameleon materials technology will now be housed at Biotectix's facility in Ann Arbor, Michigan. Biotectix will also continue the performance of active and pending projects for Chameleon customers.
New sustainable diagnostic approach offers precision cancer testing with minimal environmental impact